硼中子俘获疗法治疗复发性肝癌的初步临床研究：涉及动脉内注射含（10）BSH的WOW乳剂
Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion.
作者信息
Yanagie Hironobu, Higashi Syushi, Seguchi Koji, Ikushima Ichiro, Fujihara Mituteru, Nonaka Yasumasa, Oyama Kazuyuki, Maruyama Syoji, Hatae Ryo, Suzuki Minoru, Masunaga Shin-ichiro, Kinashi Tomoko, Sakurai Yoshinori, Tanaka Hiroki, Kondo Natsuko, Narabayashi Masaru, Kajiyama Tetsuya, Maruhashi Akira, Ono Koji, Nakajima Jun, Ono Minoru, Takahashi Hiroyuki, Eriguchi Masazumi
机构信息
Department of Innovative Cancer Therapeutics: Alpha particle and Immuno-therapeutics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Department of Nuclear Engineering & Management, Graduate School of Engineering, The University of Tokyo, Japan; Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan.
出版信息
Appl Radiat Isot. 2014 Jun;88:32-7. doi: 10.1016/j.apradiso.2014.01.014. Epub 2014 Jan 30.
A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.
一名63岁的男性，左肝叶有多个肝细胞癌，作为硼中子俘获疗法（BNCT）试点研究的首例患者入组，该研究涉及选择性动脉内注入含（10）BSH的水包油包水乳剂（（10）BSH-WOW）。在BNCT后的3个月内，肿瘤区域大小保持稳定。未观察到BNCT的不良反应。目前的结果表明，（10）BSH-WOW可作为BNCT治疗HCC时新型的动脉内硼载体。
Zotero 插件